Loading…
Epigenetic silencing of ZIC4 unveils a potential tumor suppressor role in pediatric choroid plexus carcinoma
Zic family member ZIC4 is a transcription factor that has been shown to be silenced in several cancers. However, understanding the regulation and function of ZIC4 in pediatric choroid plexus tumors (CPTs) remained limited. This study employed data mining and bioinformatics analysis to investigate th...
Saved in:
Published in: | Scientific reports 2024-09, Vol.14 (1), p.21293-13, Article 21293 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Zic family member
ZIC4
is a transcription factor that has been shown to be silenced in several cancers. However, understanding the regulation and function of
ZIC4
in pediatric choroid plexus tumors (CPTs) remained limited. This study employed data mining and bioinformatics analysis to investigate the DNA methylation status of
ZIC4
in CPTs and its correlation with patient survival. Our results unveiled
ZIC4
methylation as a segregating factor, dividing CPT cohorts into two clusters, with hyper-methylation linked to adverse prognosis. Hyper-methylation of
ZIC4
was confirmed in a choroid plexus carcinoma-derived cell line (CCHE-45) by bisulfite sequencing. Furthermore, our study demonstrated that demethylating agent and a histone methyltransferase inhibitor could reverse
ZIC4
silencing. RNA sequencing and proteomic analysis showed that
ZIC4
over-expression influenced genes and proteins involved in immune response, antigen processing and presentation, endoplasmic reticulum stress, and metabolism. Functionally, re-expressing
ZIC4
negatively impacted cell proliferation and migration. Ultimately, these findings underscore
ZIC4
hyper-methylation as a prognostic marker in CPTs and shed light on potential mechanisms underlying its tumor suppressor role in CPC. This insight paves the way for novel therapeutic targets in treating aggressive CPTs. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/s41598-024-71188-7 |